AZICO BIOPHORE INDIA PVT LTD

Overview

AZICO BIOPHORE INDIA PVT LTD is an active pharmaceutical ingredient (API) supplier with 12 active FDA Type II Drug Master Files, covering DAPAGLIFLOZIN AMORPHOUS; DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE; EMPAGLIFLOZIN; FAMOTIDINE; LEVOTHYROXINE SODIUM; LIOTHYRONINE SODIUM.

API / Drug Master Files

AZICO BIOPHORE INDIA PVT LTD holds 12 active (12 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• EMPAGLIFLOZINActive2024-12-19
• DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATEActive2024-11-02
• DAPAGLIFLOZIN AMORPHOUSActive2023-05-26
• TADALAFILActive2023-01-24
• TRICLABENDAZOLEActive2022-10-31
• PANTOPRAZOLE MAGNESIUM DIHYDRATEActive2022-01-21
• OSELTAMIVIR PHOSPHATEActive2021-08-28
• FAMOTIDINEActive2021-02-16
• PANTOPRAZOLE SODIUM USPActive2021-02-11
• LIOTHYRONINE SODIUMActive2016-09-30
• SILDENAFIL CITRATEActive2015-09-29
• LEVOTHYROXINE SODIUMActive2015-03-14

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to AZICO BIOPHORE INDIA PVT LTD in our records. PharmaTek screens the full directory against live FDA enforcement data.